Exploring the functional and prognostic roles of EPHX4 in pancreatic cancer: Insights from bioinformatics and experimental validation DOI
Shaoyang Huang,

Dandan Gu,

Wei Xiong

и другие.

Gene, Год журнала: 2025, Номер unknown, С. 149504 - 149504

Опубликована: Апрель 1, 2025

Язык: Английский

In silico pan-cancer analysis of VRAC subunits and their prognostic roles in human cancers DOI Creative Commons
Alessandro Paolì,

Soha Sadeghi,

Giulia Battistello

и другие.

Scientific Reports, Год журнала: 2025, Номер 15(1)

Опубликована: Апрель 11, 2025

Язык: Английский

Процитировано

0
Neurturin-Induced Activation of GFRA2-RET Axis Potentiates Pancreatic Cancer Glycolysis via Phosphorylated Hexokinase 2 DOI
Ran Cui, Gaoming Wang, Fuguo Liu

и другие.

Cancer Letters, Год журнала: 2025, Номер unknown, С. 217583 - 217583

Опубликована: Фев. 1, 2025

Язык: Английский

Процитировано

0
Checkpoint kinase 1 as a promising target in colorectal cancer management DOI
Wenxue Ma, Natalia Baran

World Journal of Clinical Oncology, Год журнала: 2025, Номер 16(4)

Опубликована: Март 26, 2025

This editorial provides insights into the pivotal role of checkpoint kinase 1 (CHEK1) as both a biomarker and therapeutic target in colorectal cancer (CRC), based on findings from recent study by Pang et al . Using single-cell RNA sequencing immunohistochemistry, demonstrates significant CHEK1 overexpression CRC tissues identifies nitidine chloride potent inhibitor that disrupts DNA damage repair pathways. These underscore potential inhibition highlight need for further research to address gaps treatment.

Язык: Английский

Процитировано

0
Pancreatic cancer subtyping - the keystone of precision treatment DOI Creative Commons

Zeyang Fan,

Yao Xiao, Yan Du

и другие.

Frontiers in Immunology, Год журнала: 2025, Номер 16

Опубликована: Апрель 8, 2025

In recent years, the incidence and mortality rates of pancreatic cancer have been rising, posing a severe threat to human health. Tumor heterogeneity remains critical barrier advancing diagnosis treatment efforts. The lack specific early symptoms, limited diagnostic methods, high biological complexity, restricted therapeutic options contribute poor outcomes prognosis cancer. Therefore, there is an urgent need explore different subtypes in-depth develop personalized strategies tailored each subtype. Increasing evidence highlights pivotal role molecular subtyping in treating This review focuses on advancements classifying approaches, discussed from perspectives gene mutations, genomics, transcriptomics, proteomics, metabolomics, immunomics.

Язык: Английский

Процитировано

0
Developing cell-based therapies for pancreatic ductal adenocarcinoma DOI Creative Commons
Rachel Elizabeth Ann Fincham, Joe Yeong, Hemant M. Kocher

и другие.

Journal of Clinical Investigation, Год журнала: 2025, Номер 135(8)

Опубликована: Апрель 14, 2025

Prostate stem cell antigen (PSCA) is highly and preferentially expressed on the surface of pancreatic ductal adenocarcinoma (PDAC) cells, raising promise tumor-selective cell-based immunotherapies. In this issue JCI, Dai et al. harness PSCA for development an off-the-shelf chimeric receptor (CAR) invariant natural killer T (iNKT) treatment PDAC. Through in vitro experiments vivo models, authors demonstrate selectivity therapeutic efficacy CAR_sIL15 iNKT cells against both gemcitabine-sensitive -resistant PDAC with comparable antitumor activity freshly produced frozen cells. This opens another potential option cancer.

Язык: Английский

Процитировано

0
Exploring the functional and prognostic roles of EPHX4 in pancreatic cancer: Insights from bioinformatics and experimental validation DOI
Shaoyang Huang,

Dandan Gu,

Wei Xiong

и другие.

Gene, Год журнала: 2025, Номер unknown, С. 149504 - 149504

Опубликована: Апрель 1, 2025

Язык: Английский

Процитировано

0